Background {#s1}
==========

Pancreatic cancer is a challenging disease with unfavorable outcomes. Pancreatic ductal adenocarcinoma (PDAC) constitutes around 90% of all malignant pancreatic cancers ([@B12]). As opposed to other common cancers, there has been a rise in incidence and mortality rates of PDAC ([@B30]). According to the American Cancer Society, it is the fourth leading cause of cancer-related mortality in both males and females with an estimated number of new cases and deaths in the United States in 2019 as 56,770 and 45,750, respectively ([@B32]). PDAC is associated with poor prognosis, having a 5-year survival rate of 8%, owing to its presentation as an advanced disease, being resistant to different drug regimens and a distinct tumor microenvironment with condensed desmoplasia ([@B22]; [@B37]; [@B7]; [@B8]; [@B19]). Chemotherapy, both in adjuvant and neoadjuvant settings, has remained the treatment of choice for most patients with PDAC. However, it has not been helpful in a significant improvement of survival of these patients. This leaves surgery as the only curative option but fewer than 20% of patients present with a resectable disease at diagnosis ([@B6]). The unavailability of a useful diagnostic and prognostic biomarker has always been a concern for PDAC ([@B13]).

PDAC could be associated with several targets including *KRAS*, *TP53*, *TGF-β*, *WNT*, *NOTCH*, *SMAD4*, *CDKN2A*, *ARID1A*, *MLL3*, and *TGFBR2* ([@B1]; [@B4]). Important are aberrations in BRCA and DNA repair for whom PARP-inhibitors are now an option. Small proportion (1%--2%) of PDAC is also associated with microsatellite instability (MSI) ([@B2]; [@B15]; [@B14]). MSI results from mismatch repair deficiency (dMMR) and consists of repetitive 1--6 base pairs of DNA ([@B34]; [@B15]). dMMR or loss of functional ability of any of the mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2) hinders the effective DNA replication process. Research has indicated that cancers with dMMR and MSI-H respond very well to immune checkpoint inhibitors. This implies that targeting the immune checkpoints including programmed cell death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) encourages T cells to fight cancer cells. This has been well-elaborated for melanoma and lung cancer, but data is lacking for PDAC.

Herein, we report a case of PDAC whose MSI-H status was identified on liquid biopsy which is also known as circulating tumor DNA (ctDNA) testing. Our patient showed a dramatic response to immunotherapy which was again assessed on ctDNA assays.

Case Presentation {#s2}
=================

Patient is an 81-year old female who had unrelenting pain in her stomach in January 2018. She had an ultrasound done by her gastroenterologist that showed a mass in the pancreatic head versus body. A follow-up CT scan confirmed the ultrasound findings and also showed one possible enlarged lymph node. This was followed up by MRI at Mayo Clinic, Florida in March 2018, which showed locally advanced pancreatic mass centered at the junction of the body and tail measuring 5.1 × 6.4 × 5.2 cm. The results also showed encasement of the first jejunal arterial and venous branches with adjacent mass effect causing narrowing of the superior mesenteric vein confluence. Enlarged right common iliac artery chain lymph node measuring 1.4 × 1.1 cm and indeterminate lesions in the posterior aspect of the vertebral body at T9 were noted.

A baseline ctDNA test was obtained, which is at present part of our standard of care at Mayo Clinic, Florida for patients with GI malignancies. Testing is performed through commercially available platforms. In this particular patient, this was done through Guardant360 that showed *SMAD4 R361H*, *TP53R213L*, *KRAS G12D*, *RET A640A*, *KIT K412K*, *NTRK3 R630G*, *ARID1A G1711fs* and the highest variant allele fraction was noted to be 2.2% as shown in [**Table 1**](#T1){ref-type="table"}. She was started on neoadjuvant chemotherapy with gemcitabine and paclitaxel since surgery was not an option, but there was not much response in her repeat scans in May 2018, though there was a decrease in the highest variant allele fraction to 1.2%. She was then switched to 5-fluorouracil with nanoliposomal irinotecan (5-FU was held due to *DPD* heterozygosity on pharmacogenomics testing). Repeat CT scan in July 2018 showed decrease in the size of a mass in the pancreas which measures 3.4 × 3.1 cm compared with 6.5 × 5.1 cm. Moreover, highest variant allele fraction dropped down to 0.8% on ctDNA testing in July 2018. Chemoradiation with capecitabine was added to her treatment plan in August 2018.

###### 

Serial circulating tumor DNA evaluation in our patient with MSI-H/dMMR pancreatic ductal adenocarcinoma and excellent response to pembrolizumab. As noted, the circulating tumor DNA in the *SMAD4 R361H* mutation has gone down from 2.2% to 0%.

  Serial ctDNA(liquid biopsy)testing results                                                                                                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------- -------- ---------- ------ ------
  ***Clonal Mutations***                                                                                                                                                                                                                                                                        
  *SMAD4 R361H*                                                                                                         2.2%                                                                                                     0.9%                                0.6%     0.7%       0%     0%
  *TP53 R213L*                                                                                                          1.9%                                                                                                     0.8%                                0.5%     0.6%       0%     0%
  *KRAS G12D*                                                                                                           1.9%                                                                                                     1.2%                                0.4%     0.4%       0%     0%
  *RET A640A*                                                                                                           1.6%                                                                                                     0.5%                                0.5%     0.5%       0%     0%
  *KIT K412K*                                                                                                           1.5%                                                                                                     0.4%\*                              0.3%\*   0.6%       0%     0%
  *NTRK3 R630G*                                                                                                         1.4%                                                                                                     0.6%                                0.4%     0.4%       0%     0%
  *ARID1A G1711fs*                                                                                                      1.1%                                                                                                     0.8%                                0.3%\*   0.3%\*     0%     0%
  ***Subclonal Mutations***                                                                                                                                                                                                                                                                     
  *MTOR I486V*                                                                                                          1.0%                                                                                                     0.1%                                0.3%     0.4%\*     0%     0%
  *BRCA2 A1572T*                                                                                                        0.9%                                                                                                     1.2%\*                              0.8%\*   0.5%\*     0.5%   0.4%
  *HNF1A A209T*                                                                                                         0.9%                                                                                                     0.4%                                0.4%     0.3%       0%     0%
  *ARID1A G1847G*                                                                                                       0.9%                                                                                                     0%                                  0%       0%         0%     0%
  *DDR2 K699*                                                                                                           0.7%                                                                                                     0%                                  0.2%     0%         0%     0%
  *MPL S505N*                                                                                                           0.5%                                                                                                     0%                                  0.2%     0%         0%     0%
  *PIK3CA W11R*                                                                                                         0.4%                                                                                                     0%                                  0%       0.3%       0%     0%
  *MET N1081S*                                                                                                          0.2%                                                                                                     0%                                  0%       0.2%       0%     0%
  *ATM G2675*                                                                                                           0.2%                                                                                                     0%                                  0%       0%         0%     0%
  *EGFR E543G*                                                                                                          0.1%                                                                                                     0%                                  0%       0%         0%     0%
                                                                                                                                                                                                                                                                                                
  ***MSI status***                                                                                                      ND                                                                                                       ND                                  ND       **high**   ND     ND
  ǂ ***Concordance with tissue biopsy --* clinical concordance: yes clonal concordance: yes MSI-high detection: yes**                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                
  ***Treatment***                                                                                                       **Neoadjuvant chemotherapy (gemcitabine and paclitaxel/5-fluorouracil with nanoliposomal irinotecan)**   **Immunotherapy (Pembrolizumab)**                              
  ***Tumor markers***                                                                                                                                                                                                                                                                           
  *CEA (ng/ml)*                                                                                                         15                                                                                                       11.4                                16.2     22.1       8.7    3.3
  *CA-19-9 (Units/ml)*                                                                                                  5                                                                                                        4                                   6        6          7      6

50% of the highest variant allele fraction value has been used to differentiate clonal from sub clonal mutations. \*indicates change from clonal to Subclonal and vice-versa; ND, Not Detected.

ǂBiomarker profiling on tissue sample detected SMAD4 R361H, KRAS G12D, ARID1A G1711fs mutations and MSI-high status. Therefore, ctDNA (liquid biopsy testing) is concordant with tissue biopsy testing in this patient.

In December 2018, CT scan of the chest showed a new right lower lung lobe nodule suspicious for metastatic disease along with a persistent mass in the body of the pancreas. In the repeat ctDNA testing in December 2018, she was noted to be MSI-High/mismatch repair deficient (dMMR). Furthermore, mismatch repair immunohistochemistry on the tissue sample showed loss of MLH1 and PSM2 proteins. Therefore, she was considered a great candidate for immunotherapy pembrolizumab on-label and was started on it. Dramatic improvement was noticed within 4 weeks of treatment with pembrolizumab and repeat ctDNA testing in January 2019 showed loss of all the above noted mutations. Furthermore, the highest variant allele fraction dropped down to 0.5% and patient continues to be on this therapy as depicted in [**Figure 1**](#f1){ref-type="fig"}.

![Serial liquid biopsies and changes in Highest Variant Allele Fractions of ctDNA over the course of therapy. MSI-H detected in ctDNA testing done in December 2018. MSI-H was not detected in ctDNA reports of January 2019 and February 2019.](fphar-11-00023-g001){#f1}

Discussion {#s3}
==========

The management of PDAC is a complex task. To begin with, tissue biopsy has been the diagnostic test of choice historically which is a cumbersome technique. Moreover, it is troublesome for the patients to have repeated serial tissue biopsies in order to monitor the response to therapy. In the past decade, liquid biopsy has emerged as a noninvasive and patient-convenient technique that has demonstrated the clinical utility and validity for various cancers. However, it has not been widely incorporated into clinical practice for the management of all types of cancers especially PDAC because of sparsity of evidence. Our case showed the promising role of liquid biopsy not only in detection of the underlying genetic aberration but also in determination of the treatment response in PDAC.

The available data on the prevalence of dMMR and MSI-H in PDAC is limited and heterogeneous. Previous studies have demonstrated the existence of MSI-H in PDAC, however, the findings were controversial. Yamamoto et al. investigated 103 PDAC patients and the reported incidence of MSI-H in their cohort was 16%. The researchers also reported the finding of MSI-H in 100% of their patients with hereditary PDAC (n = 3) ([@B38]). Goggins et al. studied 82 xenografts of pancreatic carcinoma and reported that 3.7% of their specimens had MSI-H ([@B10]). Ouyang et al. investigated 60 pancreatic cancer patients and found MSI-H in 9 (15%) patients of their cohort ([@B27]). Venkatasubbarao et al. reported the presence of MSI-H in 4 (29%) out of their 14 surgically resected samples of pancreatic adenocarcinoma ([@B35]). Recently, Hu et al. investigated 833 PDAC patients and found dMMR in 7 (0.8%) patients of their cohort ([@B14]). The summary of studies looking at pancreatic carcinoma and MSI-H/dMMR expression are demonstrated in [**Table 2**](#T2){ref-type="table"}. The disagreement in prevalence of MSI-H in PDAC might be due to confounding factors including differences in sample sizes, test techniques and diversity of tumor histology ([@B21]).

###### 

Summary of studies looking at pancreatic carcinoma and MSI-H/dMMR expression.

  Study      Year   Study group                                                                          MSI/MMR status                                                                                 Data source
  ---------- ------ ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  [@B33]     2019   3,594 PDAC samples                                                                   MSI-H was detected in 0.5% of samples                                                          International cohort
  [@B14]     2018   833 pancreatic adenocarcinoma patients                                               7 (0.8%) patients had dMMR, all 7 dMMR patients had lynch syndrome                             Multiple hospitals, USA
  [@B20]     2018   445 pancreatic ductal adenocarcinoma tissue samples                                  1.6% samples were dMMR                                                                         Multiple centers
  [@B15]     2017   385 pancreatic cancer tissue samples                                                 1% specimens were dMMR                                                                         Multiple centers of Australia, Germany, UK and USA
  [@B5]      2017   160 pancreatic adenocarcinoma cases from 154 patients (148 primary, 12 metastases)   4 cases were dMMR (3 had germline and 1 had somatic mutations in MMR genes)                    International Cancer Genome Consortium data portal
  [@B11]     2015   290 pancreatic ductal adenocarcinoma patients                                        4 (1.38%) patients were dMMR                                                                   Ontario Pancreas Cancer Study (Ontario population-based registry)
  [@B29]     2015   265 pancreatic ductal adenocarcinoma cases                                           41 (15%) were dMMR                                                                             Vancouver Coastal Health Region
  [@B24]     2015   282 pancreatic ductal adenocarcinoma patients                                        None of the patients had MSI-H                                                                 3 hospitals database, Japan
  [@B18]     2014   36 acinar cell carcinoma of pancreas cases                                           5 (14%) patients were dMMR                                                                     Single academic center, USA
  [@B26]     2012   78 pancreatic adenocarcinoma patients                                                13% tumors were dMMR                                                                           3 cancer treatment centers, Netherlands
  [@B23]))   2005   35 pancreatic cancer patients                                                        3 (8.6%) were dMMR who also had lynch syndrome                                                 Single academic center, USA
  [@B25]     2003   55 pancreatic carcinoma patients                                                     4 (7.3%) tumors had abnormal hMS2-negative staining                                            Single university medical center, Japan
  [@B38]     2001   103 pancreatic ductal adenocarcinoma (100 sporadic, 3 hereditary) patients           13% patients had MSI-H among sporadic PDAC group; 100% of hereditary PDAC patients had MSI-H   Single university medical center, Japan
  [@B10]     1998   82 xenografted pancreatic carcinomas                                                 3 (3.7%) specimens had MSI-H                                                                   Single academic center, USA
  [@B27]     1998   60 pancreatic cancer patients                                                        9 (15%) patients had MSI-H                                                                     Multiple hospitals, Japan
  [@B35]     1998   14 surgically resected pancreatic adenocarcinoma tissue samples                      4 (29%) had MSI-H                                                                              Single university medical center, USA

Our patient demonstrated a phenomenal response to immunotherapy. The tumor mutation burden pre- and post-treatment was well-picked on ctDNA assays. Recent research has highlighted the clinical utility and validity of ctDNA testing in the management of various gastrointestinal cancers including PDAC ([@B31]). Our findings also suggest that serial monitoring of tumor mutation burden can serve as a potential prognostic biomarker in pancreatic cancer. Previously, this was not feasible before the implication of ctDNA testing. The advent of immune checkpoint inhibitors has revolutionized the management of various MSI-H/dMMR tumors especially non-small cell lung carcinoma and melanoma. In May 2017, the United States Food and Drug Administration (FDA) approved pembrolizumab, a PD-1 inhibitor, for the treatment of MSI-H/dMMR solid tumors regardless of site of origin or histology that didn't respond or have metastasized after the introduction of first line agents ([@B17]). The role of immunotherapy in PDAC has been studied in various clinical trials, however, no objective/complete response was achieved ([@B3]; [@B28]). The potential factors responsible for resistance of PDAC to immunotherapy could be low immunogenicity, decreased tumor mutation burden and inherent quality of being unlikely to be detected by the immune system ([@B9]).

There are several ongoing clinical trials that are investigating the role of various anti-PD-1/PD-L1 agents including pembrolizumab, nivolumab, etc. as monotherapy as well as combination regimens in PDAC. A recent phase I study investigated the role of a combination regimen consisting of a tumor-associated macrophage-targeting agent cabiralizumab and the anti-PD-1 nivolumab in metastatic PDAC. The combination regimen demonstrated a confirmed objective response in 4 of 31 (13%) patients. The researchers also revealed that all of these 4 patients with confirmed objective response had MSI-H and didn't show response to anti‒PD-1 or PD-L1 monotherapy (NCT02526017) ([@B36]).

Le et al. investigated the efficacy of PD-1 blockade in the management of 12 types of solid tumors including pancreatic cancer in a multicenter phase 2 study. They enrolled all dMMR cancer patients (n = 86) who had at least one prior therapy and developed a progressive disease. The estimated objective and complete response rates were 53% and 21%, respectively. Of note, the subset analysis for pancreatic cancer (n = 8) demonstrated an objective response rate of 62%. The researchers indicated that the complete and partial responses were attained in 2 (25%) and 3 (37%) pancreatic cancer patients respectively. For the colorectal cancer (n = 40), their results showed the objective and complete response rates of 52% and 12%, respectively (NCT01876511). The study is still ongoing and manifests the value of immune checkpoint inhibitors in pancreatic cancer ([@B16]).

Conclusion and Future Directions {#s4}
================================

Pancreatic cancer is a lethal cancer with poor outcomes in spite of the recent breakthroughs in combination chemotherapy regimens. Immune checkpoint inhibitors have exhibited strong responses in several MSI-H solid tumors but there is lack of evidence regarding pancreatic cancer. Liquid biopsy could be incorporated in the management of these patients to record serial assessments of tumor mutation burden and to detect microsatellite instability, where obtaining tissue is often very difficult.

Data Availability Statement {#s5}
===========================

All datasets generated for this study are included in the article/supplementary material.

Ethics Statement {#s6}
================

Written informed consent was obtained from the patient for the publication of this case report.

Author Contributions {#s7}
====================

SK and FS drafted the initial draft manuscript with guidance from PK. Author PK revised the manuscript and further edited by all the authors. All authors approved the final draft for publication.

Conflict of Interest {#s8}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Gloria Ravegnini, University of Bologna, Italy

[^2]: Reviewed by: Marina Pajic, Garvan Institute of Medical Research, Australia; Samuel J. Klempner, Massachusetts General Hospital Cancer Center, United States

[^3]: This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology
